[1]
Janiec K,Wajgt A,Kondera-Anasz Z, Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis. Medical science monitor : international medical journal of experimental and clinical research. 2001 Jan-Feb; [PubMed PMID: 11208501]
[2]
Niezgoda A,Losy J,Mehta PD, Effect of cladribine treatment on beta-2 microglobulin and soluble intercellular adhesion molecule 1 (ICAM-1) in patients with multiple sclerosis. Folia morphologica. 2001 Aug; [PubMed PMID: 11552664]
[3]
Bartosik-Psujek H,Belniak E,Mitosek-Szewczyk K,Dobosz B,Stelmasiak Z, Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine. Acta neurologica Scandinavica. 2004 Jun; [PubMed PMID: 15147461]
[4]
Kopadze T,Döbert M,Leussink VI,Dehmel T,Kieseier BC, Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis. European journal of neurology. 2009 Mar; [PubMed PMID: 19175384]
[5]
Machado-Santos J,Saji E,Tröscher AR,Paunovic M,Liblau R,Gabriely G,Bien CG,Bauer J,Lassmann H, The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8 T lymphocytes and B cells. Brain : a journal of neurology. 2018 Jul 1; [PubMed PMID: 29873694]
[6]
Mars LT,Saikali P,Liblau RS,Arbour N, Contribution of CD8 T lymphocytes to the immuno-pathogenesis of multiple sclerosis and its animal models. Biochimica et biophysica acta. 2011 Feb; [PubMed PMID: 20637863]
[7]
Legroux L,Arbour N, Multiple Sclerosis and T Lymphocytes: An Entangled Story. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 2015 Dec; [PubMed PMID: 25946987]
[8]
Sosa RA,Forsthuber TG, The critical role of antigen-presentation-induced cytokine crosstalk in the central nervous system in multiple sclerosis and experimental autoimmune encephalomyelitis. Journal of interferon [PubMed PMID: 21919736]
[9]
Giovannoni G, Cladribine to Treat Relapsing Forms of Multiple Sclerosis. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2017 Oct; [PubMed PMID: 29168160]
[10]
Baker D,Herrod SS,Alvarez-Gonzalez C,Zalewski L,Albor C,Schmierer K, Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurology(R) neuroimmunology [PubMed PMID: 28626781]
[11]
Tintore M,Vidal-Jordana A,Sastre-Garriga J, Treatment of multiple sclerosis - success from bench to bedside. Nature reviews. Neurology. 2018 Oct 12; [PubMed PMID: 30315270]
[12]
Giovannoni G,Comi G,Cook S,Rammohan K,Rieckmann P,Soelberg S�rensen P,Vermersch P,Chang P,Hamlett A,Musch B,Greenberg SJ, A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. The New England journal of medicine. 2010 Feb 4 [PubMed PMID: 20089960]
[13]
Rommer PS,Zettl UK, Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients. Expert opinion on pharmacotherapy. 2018 Apr; [PubMed PMID: 29528247]
[15]
Kurtzke JF, Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov [PubMed PMID: 6685237]
[16]
Giovannoni G,Soelberg Sorensen P,Cook S,Rammohan K,Rieckmann P,Comi G,Dangond F,Adeniji AK,Vermersch P, Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Multiple sclerosis (Houndmills, Basingstoke, England). 2018 Oct [PubMed PMID: 28870107]
[17]
Giovannoni G,Soelberg Sorensen P,Cook S,Rammohan KW,Rieckmann P,Comi G,Dangond F,Hicking C,Vermersch P, Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Multiple sclerosis (Houndmills, Basingstoke, England). 2018 Apr 1 [PubMed PMID: 29716436]
[18]
Rammohan K,Giovannoni G,Comi G,Cook S,Rieckmann P,Soelberg Sørensen P,Vermersch P,Hamlett A,Kurukulasuriya N, Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study. Multiple sclerosis and related disorders. 2012 Jan; [PubMed PMID: 25876451]
[19]
Comi G,Cook SD,Giovannoni G,Rammohan K,Rieckmann P,Sørensen PS,Vermersch P,Hamlett AC,Viglietta V,Greenberg SJ, MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. Journal of neurology. 2013 Apr; [PubMed PMID: 23263473]
[20]
Giovannoni G,Cook S,Rammohan K,Rieckmann P,Sørensen PS,Vermersch P,Hamlett A,Viglietta V,Greenberg S, Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. The Lancet. Neurology. 2011 Apr; [PubMed PMID: 21397565]
[21]
De Stefano N,Giorgio A,Battaglini M,De Leucio A,Hicking C,Dangond F,Giovannoni G,Sormani MP, Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Multiple sclerosis (Houndmills, Basingstoke, England). 2018 Feb; [PubMed PMID: 28140753]
[22]
Leist TP,Comi G,Cree BA,Coyle PK,Freedman MS,Hartung HP,Vermersch P,Casset-Semanaz F,Scaramozza M, Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. The Lancet. Neurology. 2014 Mar [PubMed PMID: 24502830]
[23]
Boyko AN,Boyko OV, Cladribine tablets' potential role as a key example of selective immune reconstitution therapy in multiple sclerosis. Degenerative neurological and neuromuscular disease. 2018 [PubMed PMID: 30050387]
[24]
Freedman MS,Leist TP,Comi G,Cree BA,Coyle PK,Hartung HP,Vermersch P,Damian D,Dangond F, The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study. Multiple sclerosis journal - experimental, translational and clinical. 2017 Oct-Dec [PubMed PMID: 29051829]
[25]
Ali S,Paracha N,Cook S,Giovannoni G,Comi G,Rammohan K,Rieckmann P,S�rensen PS,Vermersch P,Greenberg S,Scott DA,Joyeux A, Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis : Analysis of Economic Data from the CLARITY Study. Clinical drug investigation. 2012 Jan [PubMed PMID: 27933596]
[26]
Ali S,Paracha N,Cook S,Giovannoni G,Comi G,Rammohan K,Rieckmann P,S�rensen PS,Vermersch P,Greenberg S,Scott DA,Joyeux A, Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study. Clinical drug investigation. 2012 Jan 1 [PubMed PMID: 22017519]
[27]
Soelberg Sorensen P,Giovannoni G,Montalban X,Thalheim C,Zaratin P,Comi G, The Multiple Sclerosis Care Unit. Multiple sclerosis (Houndmills, Basingstoke, England). 2018 Oct 23 [PubMed PMID: 30351211]
[28]
Mattarozzi K,Baldin E,Zenesini C,Solari A,Amato MP,Leone M,Mancardi G,Martinelli V,Savettieri G,Solaro C,Tola MR,D'Alessandro R, Effect of organizational features on patient satisfaction with care in Italian multiple sclerosis centres. European journal of neurology. 2017 Apr; [PubMed PMID: 28220581]